Bristol Myers’ (BMY) is striving hard for the label expansion of its key drugs. The company’s growth portfolio comprises ...

Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent ...

(Reuters) -Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

Bristol Myers' Reblozyl missed its primary goal in a Phase 3 anemia trial but showed positive secondary outcomes in ...

Despite the failure, BMS remains “encouraged” by Reblozyl’s clinical activity in myelofibrosis-associated anemia and will approach regulators to discuss potential submissions for this indication, for ...

Bristol Myers on Friday said the Phase 3 study of Reblozyl with concomitant janus-kinase-inhibitor therapy didn't meet its primary endpoint of red-blood-cell transfusion independence in adults with ...

Health Canada's approval of REBLOZYL ® is based upon findings from the phase 3, double-blind, randomized, placebo-controlled BELIEVE study, which compared treatment with REBLOZYL ® and best ...

Reblozyl (luspatercept-aamt), a first-in-class erythroid maturation agent, promotes late-stage red blood cell maturation in animal models. Bristol Myers Squibb and Acceleron are jointly developing ...

SUMMIT, N.J.& CAMBRIDGE, Mass.---- Celgene Corporation and Acceleron Pharma Inc. today announced the U.S. Food and Drug Administration has approved REBLOZYL ® for the treatment of anemia in adult ...

Reblozyl is also approved for the treatment of anemia in adults with beta thalassemia who require RBC transfusions; and for the treatment of anemia failing an ESA and requiring 2 or more RBC units ...